A groundbreaking project to study potential HIV vaccines in several African countries has been derailed by an abrupt cut in ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Early diagnosis and prompt antiretroviral therapy initiation are critical for children due to the rapid progression of HIV in ...

The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...

The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of antiretrovirals to one-month refills since the U.S. government froze foreign ...

The system of finding, diagnosing and treating TB has collapsed in dozens of countries across Africa and Asia since President Trump ordered the aid freeze.

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Let’s take your partner’s HIV status out of the equation for a moment. You’re looking at a person who has a concerning temper, refuses to admit faults (and, therefore, probably refuses to work on them ...

Researchers from Imperial College London, working with the University of Oxford and Rockefeller University, have shown ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...